| Document |
Document Title |
|
WO/2010/068710A2 |
The disclosure relates to novel compounds that are capable of modulating Jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a Jak2 mediated disease or disorder...
|
|
WO/2010/061382A2 |
A process for preparing a substituted aromatic compound, comprising combining an aromatic compound and cuprous (Cu+) ions in a reaction vessel in an essentially oxygen-free environment, and adding to said reaction vessel a source of an e...
|
|
WO/2010/060390A1 |
A method of preparation of 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol of formula (I), known under the generic name desvenlafaxine, and its pharmaceutically acceptable salts, which comprises (a) stirring up O-benzyl desvenla...
|
|
WO/2010/055028A2 |
The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
|
|
WO/2010/055027A2 |
The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20- alky-phenyl)ethyl]propane~1,3~diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
|
|
WO/2010/052181A2 |
The present invention relates to a method for producing N,N-substituted-3-aminopropan-1-ols by a) converting secondary amine with acrolein at a temperature of (-50) to 100°C and a pressure of 0.01 to 300 bar, and b) converting the react...
|
|
WO/2010/049293A2 |
A process for preparing N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)-phenyl]p
ropan-1-amine of formula (I) i.e. Cinacalcet and its intermediates of formulae (V), (Va) and (Vb).
|
|
WO/2010/047318A1 |
Disclosed are novel helicene derivative, axially asymmetric amino acid, amine or aminoalcohol derivative, and azaperylene derivative. The inventors have created compounds each represented by general formula (I), (I'), (II), (II') or (III...
|
|
WO/2010/043000A1 |
The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions cau...
|
|
WO/2010/043571A1 |
The present invention describes a novel process for the preparation of optically active (S)-(-)-2-(N-propylamino)-5-methoxytetraline and (S)-(-)-2-(N-propylamino)-5- hydroxytetraline compounds based on the optical resolution of mixtures ...
|
|
WO/2010/042998A1 |
The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pha...
|
|
WO/2010/042164A2 |
A method of transalkoxylation of nucleophilic compounds in which an alkoxylated and a nucleophilic compound are combined in a suitable vessel and reacted in the presence of a heterogeneous catalyst under conditions capable of transferrin...
|
|
WO/2010/042168A2 |
The present invention relates to processes for the manufacture of one or more ethanolamines and one or more ethyleneamines starting from the reaction of ethylene oxide with ammonia to produce one or more ethanolamines and the conversion ...
|
|
WO/2010/041964A1 |
A method for preparing an alkenylamine, or a salt, solvate or hydrate thereof, is disclosed. The method comprises reacting a alogen-substituted cyclic acetal or a derivative thereof under particular conditions to provide the alkenylamine...
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/037531A1 |
The present invention relates to a method for producing substituted 3-aminobiphenylene and derivatives thereof (formula 3). Functionalized biphenyl compounds are particularly of interest as pharmaceuticals and crop protection agents and ...
|
|
WO/2010/035111A1 |
A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid- sodium boron hydride complex and which make...
|
|
WO/2010/008735A9 |
The present invention provides crystalline and amorphous salts of O- desmethylvenlafaxine and processes for preparing said salts of O- desmethylvenlafaxine. The present invention further provides pharmaceutical compositions comprising sa...
|
|
WO/2010/030017A1 |
A method for producing an optically active cyclopropane carboxylic acid ester compound represented by formula (4), said method being characterized in that a diazoacetic acid ester represented by formula (2) and a compound represented by ...
|
|
WO/2010/028130A2 |
The present invention relates to deuterated forms of desvenlafaxine and the use of such compounds in pharmaceutical composition and for treatment of psychological disorders.
|
|
WO/2010/025366A2 |
A method of performing a chemical reaction includes reacting an allyl donor and a substrate in a reaction mixture, and forming a homoallylic alcohol in the reaction mixture. The substrate may be an aldehyde or a hemiacetal. The reaction ...
|
|
WO/2010/023535A1 |
Disclosed herein are novel intermediates and process for large scale production of (S)- 3-[(1-dimethylamino) ethyl] phenyl-N-ethyl-N-methyl-carbamate (rivastigmine) or its pharmaceutically acceptable salts employing the novel intermediat...
|
|
WO/2010/015107A1 |
The present invention discloses an intermediate compound for preparing valiolamine and a method for stereoselective synthesis of valiolamine. The intermediate compound possesses chemical structure of formula (21). The said method compris...
|
|
WO/2010/013050A1 |
The present invention provides a convenient and efficient process for the preparation of O-desmethylvenlafaxine (ODV) or a salt thereof, comprising the reaction of venlafaxine, or a salt thereof, with a thiourea or a mixture of thioureas.
|
|
WO/2010/013809A1 |
Provided are optically active titanium-salan compounds useful for asymmetric epoxidation and a process for efficient production thereof. In isolating an optically active titanium-salan compound useful for asymmetric epoxidation as a di-Î...
|
|
WO/2010/000015A1 |
A salt of a sulfonated dye comprising an ammonium cation as a counterion. The ammonium cation comprises at least 3 hydroxyl groups. The salt is useful in reducing kogation in thermal inkjet printheads. One example of these salts is the c...
|
|
WO/2009/156620A1 |
The degradation of an absorbent solution comprising organic compounds provided with an amino functional group, in aqueous solution, is substantially reduced in the presence of a small amount of multisulphur‑containing degradation-inhib...
|
|
WO/2009/156622A1 |
The degradation of an absorbing solution containing organic compounds having an amine function in aqueous solution is substantially reduced in the presence of a small quantity of sulphurated degradation inhibiting agents defined by gener...
|
|
WO/2009/156621A1 |
The degradation of an absorbent solution comprising organic compounds provided with an amino functional group, in aqueous solution, is substantially reduced in the presence of a small amount of sulphur‑containing degradation-inhibiting...
|
|
WO/2009/154754A2 |
The present invention is directed to a process for preparing a 2,26,6-d 4 -morpholine derivative represented by Structural Formula (I), or a salt thereof.
|
|
WO/2009/155488A2 |
The present invention relates to a novel salt and crystal of the Active Pharmaceutical Ingredient (API) O-Desmethylvenlafaxine, including methods of making the salt and crystal, pharmaceutical compositions comprising the salt and crystal...
|
|
WO/2009/151494A1 |
The present invention provides isolated O-desmethylvenlafaxine impurities ODV-Dimer and ODV-N-Dimer, their use as a reference marker and reference standard, and a process for the preparation of O-desmethylvenlafaxine free from said impur...
|
|
WO/2009/150118A2 |
A series of novel salt forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbony
l]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
|
|
WO/2009/149622A1 |
6-Nitro acetophenone compounds of Formula (I), wherein the substituents are defined as the specification, preparation methods, uses in the preparation of 3-substituent-4-hydroxyquinoline and 3-substituent-4-chloroquinoline compounds, and...
|
|
WO/2009/147524A1 |
An apparatus for producing a mono (lower alkyl) monoalkanolamine according to the present invention includes a reaction distillation tower (12) into which a mixed raw material (11) containing a mono (lower alkyl) amine (AA: raw material ...
|
|
WO/2009/147141A2 |
The invention relates to functionalised diols of diamondoids wherein one of the two hydroxy groups is masked by a protective group, and to methods for producing said functionalised diols. The protective group is a -CHR1R2 group, wherein ...
|
|
WO/2009/147632A2 |
The invention provides a method of preparing the stereoisomers of 1,11-diamino-6-aza- undecane-2,4,8,10-tetraol.
|
|
WO/2009/145280A1 |
An apparatus for producing a mono(lower alkyl)monoalkanolamine provided with a reaction/distillation column (12) into which a material mixture (11) consisting of a mono(lower alkyl)amine (AA: starting material I) and an alkylene oxide (A...
|
|
WO/2009/144848A1 |
Disclosed are a method and an apparatus for producing a mono-lower-alkyl monoalkanol amine. The apparatus comprises: a reaction column (12) into which a mixed starting material (11) comprising a mono-lower-alkyl amine (AA: a starting mat...
|
|
WO/2009/144517A1 |
The present invention relates to a process for the preparation of cyclohexanol derivatives of the general formula (I), wherein R stands for a hydrogen atom or a methyl group, in a one-step process from a cyano compound of the general for...
|
|
WO/2009/138235A1 |
The present invention relates to a process for the preparation of a salt of O-desmethylvenlafaxine comprising a) dissolving or suspending O-desmethylvenlafaxine in the form of its base in a liquid medium selected from the group of solven...
|
|
WO/2009/138234A1 |
The present invention relates to a process for the preparation of a salt of O-desmethylvenlafaxine comprising a) dissolving or suspending O-desmethylvenlafaxine in the form of its base in a liquid medium selected from the group of solven...
|
|
WO/2003/096987A9 |
|
|
WO/2009/133052A1 |
The present invention relates to a compound of formula (I), including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptab...
|
|
WO/2009/130873A1 |
Disclosed is a hydrofluoroalkane sulfonate having good conductivity and excellent biodegradability. A conductive composition containing the hydroalkane sulfonate, an antistatic agent composed of the conductive composition, and a method f...
|
|
WO/2009/129097A1 |
Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compoun...
|
|
WO/2009/118168A1 |
The invention relates to compounds which have an affinity to the µ-opioid receptor and ORL1 receptor, to processes for preparation thereof, to medicaments comprising these compounds and to the use of these compounds for producing medica...
|
|
WO/2009/118758A2 |
Crystalline Form V of O-desmethylvenlafaxine succinate, wherein the crystalline form exhibits an X-Ray Powder Diffraction pattern having characteristic peaks expressed in degrees 2θ ( ±0.2° 2θ ) at 12.15, 13.17, 14.67, 15.8, 19.69, 2...
|
|
WO/2009/118171A1 |
The invention relates to compounds having an affinity for the μ-opioid receptor and the ORL1 receptor, to a method for the production thereof, to a pharmaceutical comprising said compounds, and to the use of said compounds for the produ...
|
|
WO/2009/115534A1 |
The present invention relates to improved processes for the production of 2-amino-2-[2-(4- C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein.
|
